Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect (Q53343243)
scientific article published in August 1999
Language:
Current Data About Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect
(P31) (Q13442814)
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P50) (Q43042749)
(P1545) 4
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P304) 263-273
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P407) (Q1860)

(P433) 2
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P478) 44
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P577) Sunday, August 1, 1999
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P921) (Q181600)

(Q1431847)
(P887)

(Q424027)
(P887)

(Q415739)
(P887)

(P1104) 11
(P887)

(P1433) (Q6294770)
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P1476) "Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect" (language: en)
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P2093) Nichols RL
(P1545) 1
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Graham DR
(P1545) 2
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Barriere SL
(P1545) 3
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Wilson SE
(P1545) 5
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Zervos M
(P1545) 6
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Dunn DL
(P1545) 7
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

Kreter B
(P1545) 8
(P248)
(P698) 10473234
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/10473234

(P2860) (Q54267475)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FJAC%2F44.2.263
(P813) Sunday, January 21, 2018

(Q52895239)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FJAC%2F44.2.263
(P813) Sunday, January 21, 2018

(Q40767561)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FJAC%2F44.2.263
(P813) Sunday, January 21, 2018

other details
description scientific article published in August 1999

External Links
(P356) 10.1093/JAC/44.2.263
(P698) 10473234
(P5875) 31263885